Catabasis Pharmaceuticls Inc. (NASDAQ:CATB)‘s stock had its “outperform” rating reiterated by Wedbush in a report released on Thursday. They presently have a $17.00 price objective on the stock. Wedbush’s price target would suggest a potential upside of 249.79% from the company’s previous close.

Separately, Zacks Investment Research raised shares of Catabasis Pharmaceuticls from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a report on Tuesday, July 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $19.05.

Catabasis Pharmaceuticls (NASDAQ:CATB) traded up 3.18% during trading on Thursday, reaching $4.86. The company’s stock had a trading volume of 152,966 shares. Catabasis Pharmaceuticls has a 52 week low of $3.31 and a 52 week high of $10.83. The company’s 50 day moving average price is $4.77 and its 200 day moving average price is $4.74. The company’s market cap is $74.75 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Catabasis Pharmaceuticls (NASDAQ:CATB) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.04. On average, equities analysts anticipate that Catabasis Pharmaceuticls will post ($2.47) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Catabasis Pharmaceuticls stock. Sphera Funds Management LTD. raised its stake in shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) by 184.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 230,041 shares of the company’s stock after buying an additional 149,299 shares during the period. Sphera Funds Management LTD. owned 1.50% of Catabasis Pharmaceuticls worth $1,159,000 as of its most recent SEC filing. 57.27% of the stock is currently owned by institutional investors and hedge funds.

Catabasis Pharmaceuticls Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

5 Day Chart for NASDAQ:CATB

Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with's FREE daily email newsletter.